Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Trial Profile

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIC
  • Sponsors ARIAD Pharmaceuticals; Takeda Development Center Americas; Takeda Pharma
  • Most Recent Events

    • 12 Dec 2023 Results of long-term 4-year update of efficacy and safety outcomes , presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 20 Oct 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
    • 15 Jun 2023 Results of post hoc analysis (n=282) from the 3-year update of the Optic trial assessing the efficacy and safety of 3 starting doses of Ponatinib in patients with chronic-phase chronic myeloid leukemia, presented at the 28th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top